CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $22,173,750 | +25.6% | 2,025,000 | 0.0% | 2.49% | -7.3% |
| Q1 2023 | $17,658,000 | +48977.3% | 2,025,000 | -64.7% | 2.69% | -50.4% |
| Q4 2022 | $35,980 | -99.8% | 5,738,500 | 0.0% | 5.42% | +67.9% |
| Q3 2022 | $20,085,000 | +18.6% | 5,738,500 | 0.0% | 3.23% | -9.8% |
| Q2 2022 | $16,929,000 | -5.1% | 5,738,500 | 0.0% | 3.58% | -10.2% |
| Q1 2022 | $17,847,000 | -2.6% | 5,738,500 | +5.9% | 3.99% | -6.1% |
| Q4 2021 | $18,319,000 | +20.4% | 5,419,896 | +30.0% | 4.24% | +5.7% |
| Q3 2021 | $15,220,000 | -1.1% | 4,169,896 | +18.1% | 4.01% | -25.1% |
| Q2 2021 | $15,388,000 | +13.6% | 3,529,465 | +18.3% | 5.36% | -0.6% |
| Q1 2021 | $13,545,000 | +58.8% | 2,983,513 | +100.8% | 5.40% | +16.3% |
| Q4 2020 | $8,530,000 | – | 1,486,107 | – | 4.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 1,653,495 | $10,367,414 | 8.97% |
| Versant Venture Management, LLC | 543,753 | $3,409,330 | 7.06% |
| TCG Crossover Management, LLC | 5,905,400 | $37,026,858 | 6.54% |
| COMMODORE CAPITAL LP | 5,738,500 | $35,980 | 5.42% |
| Foresite Capital Management IV, LLC | 1,787,094 | $11,205,079 | 4.79% |
| Saturn V Capital Management LP | 1,611,778 | $5,718,432 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 1,015,000 | $6,364,050 | 3.92% |
| Altium Capital Management LP | 1,025,000 | $6,426,750 | 3.27% |
| Affinity Asset Advisors, LLC | 1,143,531 | $7,169,939 | 2.81% |
| GREAT POINT PARTNERS LLC | 1,550,000 | $9,718,500 | 1.90% |